Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fipamezole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.57 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.57 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 2/20 | 0.30 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.30 |
| ▸ | HTR5A | P47898 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fipamezole SCHEMBL1271449 | 1.00 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1BHTR1D | |
| Fipamezole SCHEMBL3901401 | 0.99 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1BHTR1D | |
| Fipamezole SCHEMBL9354688 | 0.91 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL4626063 | 0.86 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL8612885 | 0.84 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1BHTR1D | |
| SCHEMBL8610304 | 0.84 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL7642900 | 0.84 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| Atipamezole SCHEMBL881064 | 0.83 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1BAXL | |
| SCHEMBL7645070 | 0.82 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CADRA1BHTR5A | |
| Atipamezole SCHEMBL31147780 | 0.81 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2024-12-12 | — | — | US | claimed |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | MELIOR PHARMACEUTICALS II, LLC (US) | 2024-07-30 | — | — | US | claimed |
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | MELIOR PHARMACEUTICALS II, LLC | 2022-10-20 | — | — | US | claimed |
| US-20220257590-A1 | METHOD OF TREATING DYSKINESIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-08-18 | — | — | US | claimed |
| US-8653122-B2 | Oromucosal formulation and process for preparing the same | SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD. (CH) | 2014-02-18 | — | — | US | claimed |
| CN-1711083-B | Oral mucosa formulation and process for preparing the same | PHARMA SCHWEIZ AG | 2010-05-12 | — | — | CN | claimed |
| EP-1610771-B1 | USE OF AN ALPHA2-ADRENOCEPTOR ANTAGONIST FOR THE TREATMENT OF EPILEPSY | ORION CORP (FI) | 2008-12-03 | — | — | EP | claimed |
| US-20080207719-A1 | Treatment of Epilepsy | ORION CORPORATION (FI) | 2008-08-28 | — | — | US | claimed |
| EP-1333828-B1 | PREVENTION OF DEVELOPMENT OF DYSKINESIAS | ORION CORP (FI) | 2008-07-02 | — | — | EP | claimed |
| EP-1560581-B1 | OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME | JUVANTIA PHARMA LTD OY (FI) | 2007-01-10 | — | — | EP | claimed |
| US-20040039041-A1 | Prevention of development of dyskinesias | ORION CORPORATION (FI) | 2004-02-26 | — | — | US | claimed |
| WO-2003082275-A1 | TREATMENT OF DEPENDENCE AND DEPENDENCE RELATED WITHDRAWAL SYMPTOMS | ORION CORPORATION (FI) | 2003-10-09 | — | — | WO | claimed |
| EP-1333828-A2 | PREVENTION OF DEVELOPMENT OF DYSKINESIAS | ORION CORPORATION (FI) | 2003-08-13 | — | — | EP | claimed |
| US-20020115703-A1 | Prevention of development of dyskinesias | ORION CORPORATION (FI) | 2002-08-22 | — | — | US | claimed |
| WO-2002039991-A2 | PREVENTION OF DEVELOPMENT OF DYSKINESIAS | ORION CORPORATION (FI) | 2002-05-23 | — | — | WO | claimed |
| JP-3276371-B2 | — | — | 2002-04-22 | — | — | JP | claimed |
| EP-0618906-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | JUVANTIA PHARMA LTD OY (FI) | 1998-04-22 | — | — | EP | claimed |
| US-5498623-A | MULTISTAGE REACTION FOR HALOGENATION OF COMPOUNDS, NITRATION, REDUCTION AND CONVERSION TO DIAZONIUM SALT THEN HALOGENATION FOR COGNITIVE DISORDERS | ORION-YHTYMA OY (FI) | 1996-03-12 | — | — | US | claimed |
| EP-0618906-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ANTII SAKARI HAAPALINNA (FI) | 1994-10-12 | — | — | EP | claimed |
| WO-1993013074-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Orion-Yhtymä Oy (FI) | 1993-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331320-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | ADRA2A 824/4885ADRA2B 995/4885ADRA2C 427/4885 |
| US-20240408090-A1 | Methods Of Treating Dyskinesia And Related Disorders | SLC6A3, CHAT, ACHE | ADRA2A 824/4885ADRA2B 995/4885ADRA2C 427/4885 |
| US-20220257590-A1 | METHOD OF TREATING DYSKINESIA | OPRM1, OPRK1, OPRD1 | ADRA2A 31/4885ADRA2B 83/4885ADRA2C 73/4885 |
| US-12048697-B2 | Methods of treating dyskinesia and related disorders | SLC6A3, CHAT, ACHE | ADRA2A 824/4885ADRA2B 995/4885ADRA2C 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.